Biotech Startups

Profionics develops host-response biomarker technology for rapid detection and diagnosis of sepsis. The company serves healthcare providers and operates in the diagnostic and biotech sectors.

1 investor

Progentec develops diagnostic and digital health solutions for autoimmune disease detection and treatment, including biomarker tests and remote monitoring technologies for clinicians and patients. The company focuses on improving health outcomes for the 25 million Americans living with autoimmune diseases.

1 investor

Progressive NEURO, Inc. develops medical devices for the treatment of ischemic stroke, including products that go beyond traditional aspiration and thrombectomy to improve first-pass efficacy and reduce distal emboli and vessel wall trauma. The company holds seven issued patents covering five different products.

1 investor

Wyss Zurich is a translational accelerator embedded within ETH Zurich and the University of Zurich, providing funding, infrastructure, technology platforms, and entrepreneurial support to early-stage projects. It focuses on regenerative medicine, robotics, and medical devices/bionics, helping move academic research toward clinical and commercial application.

1 investor

Prolight Diagnostics develops the Psyros platform, a point-of-care diagnostic system designed to deliver laboratory-quality test results at the patient bedside with speed and cost-effectiveness. The company serves clinical diagnostics markets including traumatic brain injury and cardiac biomarkers.

1 investor

Prologue Medicines is a biotech company exploring the viral proteome using machine learning and next-generation sequencing to identify virus-evolved proteins and design programmable protein-based medicines. Founded by Flagship Pioneering, it aims to develop therapeutics that modulate human physiology beyond what human proteins can achieve.

1 investor

Promed Bioscience develops, manufactures, and supplies highly purified research and medical grade collagen extracted from animal tissue using proprietary methods. It provides collagen-based formulations, biomaterials, and devices customized for research, clinical, and cosmetic/skincare applications, sold through worldwide channels and partners.

1 investor

Promega provides a portfolio of reporter bioassays used to characterize and develop monoclonal antibody and cell-based therapeutics for drug developers. The assays measure biological functions including Fc effector activity, immune checkpoint modulation, T cell activation, and cytokine signaling.

1 investor

Prometheus Laboratories is a specialty clinical laboratory that discovers, develops, and commercializes diagnostic testing services for Inflammatory Bowel Disease and other gastrointestinal disorders. Its tests help clinicians with disease stratification, therapy selection, treatment optimization, and monitoring across the patient journey.

1 investor

Promis Diagnostics develops noninvasive tests for early detection of colorectal, bladder, and lung cancer using its patented LTE-qMSP technology, which uses methylated DNA as biomarkers via PCR. The company targets patients seeking accessible and affordable cancer screening options.

1 investor

ProNovo Therapeutics is a biotechnology company developing precision small-molecule therapeutics for neuropsychiatric disorders, including Major Depressive Disorder and Schizophrenia. The company applies a precision-medicine approach based on genetic susceptibility, disease pathophysiology, and biomarkers to advance preclinical drug programs toward clinical development.

1 investor

ProPharma provides outsourced clinical, regulatory, and quality staffing solutions for pharmaceutical and biotech companies through a flexible staffing partnership (FSP) model. The company supplies experienced professionals from a global network to support drug development and compliance-related functions.

1 investor

PROSION Therapeutics develops platform technology for oncology and other diseases based on research into protein targets like Ena/VASP; the company translates academic research into clinical treatments for conditions with significant patient impact.

1 investor

Prota Therapeutics is a late clinical-stage biotech company developing allergen oral immunotherapies to treat food allergies, with a lead phase-3-ready product (PRT120) targeting peanut allergy. Its technology originated from research led by Professor Mimi Tang at the Murdoch Children's Research Institute in Melbourne, Australia.

1 investor

Protara develops transformative therapies for patients with cancer and rare diseases, applying modern scientific and manufacturing advancements to accelerate drug development.

1 investor

Protedyne develops laboratory automation platforms for pharmaceutical, biotech, and diagnostic testing companies to handle high-volume testing with rapid turnaround times. The company applies industrial automation design principles to laboratory equipment serving clinical and research environments.

1 investor

Proteine Resources develops insect-based bio-protein and premium pet food using biotechnology, AI, and regenerative agriculture. The company supplies both ingredient solutions and white-label products to pet food brands with a focus on sustainability, cost efficiency, and consistent nutritional quality.

1 investor

ProteoFormiX applies top-down proteomics to biobanked clinical tissue and liquid biopsy samples to identify human proteoforms and discover biomarkers for drug development and diagnostics. It focuses on neurodegenerative disorders, hard-to-diagnose diseases such as cancer, and biofluid-based proteomics (e.g. tears in ophthalmology), working with hospital pathology departments and pharmaceutical research groups.

1 investor

ProteomEdge develops mass spectrometry-based analytical platforms and proprietary heavy-labelled protein standard panels for absolute protein quantification in blood plasma, targeting clinically relevant biomarkers such as apolipoproteins, complement factors, and liver disease markers. Its products serve research and translational proteomics customers, including academic core facilities and precision medicine researchers. Based in Stockholm, Sweden.

1 investor

Proteros provides structural biology, cryo-EM, protein sciences, and biophysics research services for drug discovery and development. The company operates cutting-edge laboratory facilities in the Munich biotech cluster in Germany.

1 investor

Proterro uses a patented technology platform to convert captured waste CO2 into high-value products across two categories, Proterro Sugars and Proterro Nutritionals. It works with partners to develop custom molecules and products tailored to their specifications, purity standards, and supply requirements.

1 investor

Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins. The company leverages its scientific legacy from Athena Neurosciences and collaborates with academic and industry partners to advance its pipeline of novel therapeutic candidates.

1 investor

ProThera Biologics develops therapies based on Inter-alpha inhibitor proteins (IAIP), a class of human plasma proteins with anti-inflammatory activity, to treat patients with severe inflammatory diseases. The company targets life-threatening immune responses associated with high mortality in intensive care settings.

1 investor

Protiva develops nature-derived pigments engineered for industrial use, offering traceable, certified colorants validated to work within existing manufacturing processes without hazardous chemistry. The company targets industry as a sustainable alternative in the materials and colorants sector.

1 investor